Physician profile
Damon Morris Mcclain
NPI 1063747178
$5,875.75
in general payments reported to CMS, 2019-2025
26 companies · $1,132 in 2025
The $1,132 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $570 · 2020: $264 · 2021: $519 · 2022: $1,108 · 2023: $1,054 · 2024: $1,228 · 2025: $1,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,316 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,315.67 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $985.37 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Abbvie INC. | $892.48 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $687.69 | 2019-2025 | |
| Genzyme Corporation | $543.57 | 2020-2025 | |
| Lilly USA, LLC | $352.23 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Sun Pharmaceutical Industries INC. | $304.41 | 2019-2025 | Ilumya |
| Ucb, INC. | $293.01 | 2023-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $253.35 | 2019-2025 | |
| Incyte Corporation | $234.28 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $219.90 | 2023-2025 | Sotyktu |
| Amgen INC. | $174.24 | 2020-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $161.67 | 2019-2025 | Nemluvio |
| Journey Medical Corporation | $152.00 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $133.36 | 2019-2025 | Dupixent |
| Dermavant Sciences, INC. | $118.51 | 2022-2024 | Vtama |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $89.93 | 2025 | Vtama, Nexplanon |
| Leo Pharma INC. | $48.92 | 2022-2023 | Adbry |
| Arcutis Biotherapeutics, INC. | $39.24 | 2023-2024 | Zoryve |
| Mayne Pharma Commercial LLC | $38.34 | 2025 | |
| Almirall LLC | $36.14 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $26.92 | 2019-2022 | |
| Helsinn Therapeutics (U.S.), INC. | $21.43 | 2020 | |
| Dermira, INC. | $21.42 | 2019 | |
| Mckesson Medical-Surgical, INC. | $20.00 | 2021 | |
| Celgene Corporation | $13.71 | 2019 | |
| Strata Skin Sciences, INC. | $13.63 | 2025 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Damon Mcclain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.